VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection

Teclegiorgis Gebremariam; Nathan P. Wiederhold; Annette W. Fothergill; Edward P. Garvey; William J. Hoekstra; Robert J. Schotzinger; Thomas F. Patterson; Scott G. Filler; Ashraf S. Ibrahim

doi:10.1128/AAC.01437-15

VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection

Teclegiorgis Gebremariam, Nathan P. Wiederhold, Annette W. Fothergill, Edward P. Garvey, William J. Hoekstra, Robert J. Schotzinger, Thomas F. Patterson, Scott G. Filler, Ashraf S. Ibrahim

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.

Original language	English (US)
Pages (from-to)	7815-7817
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	59
Issue number	12
DOIs	https://doi.org/10.1128/AAC.01437-15
State	Published - Dec 1 2015

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.01437-15

Fingerprint Dive into the research topics of 'VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection'. Together they form a unique fingerprint.

Cite this

VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection. / Gebremariam, Teclegiorgis; Wiederhold, Nathan P.; Fothergill, Annette W.; Garvey, Edward P.; Hoekstra, William J.; Schotzinger, Robert J.; Patterson, Thomas F.; Filler, Scott G.; Ibrahim, Ashraf S.

In: Antimicrobial agents and chemotherapy, Vol. 59, No. 12, 01.12.2015, p. 7815-7817.

Research output: Contribution to journal › Article › peer-review

Gebremariam, Teclegiorgis ; Wiederhold, Nathan P. ; Fothergill, Annette W. ; Garvey, Edward P. ; Hoekstra, William J. ; Schotzinger, Robert J. ; Patterson, Thomas F. ; Filler, Scott G. ; Ibrahim, Ashraf S. / VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection. In: Antimicrobial agents and chemotherapy. 2015 ; Vol. 59, No. 12. pp. 7815-7817.

@article{48958103aeaf42ed98172de86f645cbe,

title = "VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection",

abstract = "We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.",

author = "Teclegiorgis Gebremariam and Wiederhold, {Nathan P.} and Fothergill, {Annette W.} and Garvey, {Edward P.} and Hoekstra, {William J.} and Schotzinger, {Robert J.} and Patterson, {Thomas F.} and Filler, {Scott G.} and Ibrahim, {Ashraf S.}",

note = "Funding Information: This work was supported by Public Health Service contract HHSN272201000038I (NIH task order A13) and grant R01 AI063503. Research described in the manuscript was partly conducted at the research facilities of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. VT-1161 powder was provided by Viamet Pharmaceuticals, Inc. Plasma concentrations were determined at OpAns, LLC (Durham, NC).",

year = "2015",

month = dec,

day = "1",

doi = "10.1128/AAC.01437-15",

language = "English (US)",

volume = "59",

pages = "7815--7817",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "12",

}

TY - JOUR

T1 - VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection

AU - Gebremariam, Teclegiorgis

AU - Wiederhold, Nathan P.

AU - Fothergill, Annette W.

AU - Garvey, Edward P.

AU - Hoekstra, William J.

AU - Schotzinger, Robert J.

AU - Patterson, Thomas F.

AU - Filler, Scott G.

AU - Ibrahim, Ashraf S.

N1 - Funding Information: This work was supported by Public Health Service contract HHSN272201000038I (NIH task order A13) and grant R01 AI063503. Research described in the manuscript was partly conducted at the research facilities of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. VT-1161 powder was provided by Viamet Pharmaceuticals, Inc. Plasma concentrations were determined at OpAns, LLC (Durham, NC).

PY - 2015/12/1

Y1 - 2015/12/1

N2 - We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.

AB - We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.

UR - http://www.scopus.com/inward/record.url?scp=84954496267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954496267&partnerID=8YFLogxK

U2 - 10.1128/AAC.01437-15

DO - 10.1128/AAC.01437-15

M3 - Article

C2 - 26369977

AN - SCOPUS:84954496267

VL - 59

SP - 7815

EP - 7817

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -